Clinical Trials Sponsored by Candler Hospital

Total 128153 results

Fujian Cancer Hospital

Not yet recruiting

Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer

Cervical Cancer
Zhejiang Cancer Hospital

Recruiting

Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.

Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed

China
Zhejiang Cancer Hospital

Recruiting

Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma

Bile Duct Adenocarcinoma

China
Zhejiang Cancer Hospital

Recruiting

A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma Refractory

China
Hubei Cancer Hospital

Recruiting

Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade

Nausea With Vomiting Chemotherapy-Induced

China
Fujian Cancer Hospital

Recruiting

Radiotherapy Combined With TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma

Stage IIIA Hepatocellular Carcinoma

China
Zhejiang Cancer Hospital

Recruiting

Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Hubei Cancer Hospital

Recruiting

Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy

Radiotherapy | Immunotherapy | Advanced Non-Small Cell Squamous Lung Cancer

China
Hubei Cancer Hospital

Recruiting

Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients

Metastatic Lung Cancer | Elderly Patients

China
Zhejiang Cancer Hospital

Recruiting

XPO-1 in Combination With RCHOP for DH/TH Lymphoma

Double Hit Lymphoma | Triple Hit Lymphoma

China
Henan Cancer Hospital

Recruiting

Go-CHOP as the Frontline Therapy for PTCL

Peripheral T Cell Lymphoma

China
Henan Cancer Hospital

Recruiting

A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer

HER2 Low Breast Carcinoma

China
Fujian Cancer Hospital

Recruiting

Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin

Carcinoma | Cervix Carcinoma

China
Fujian Cancer Hospital

Not yet recruiting

A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses

Hepatocellular Carcinoma
Henan Cancer Hospital

Recruiting

Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin

Squamous Cell Carcinoma of the Skin

China
Zhejiang Cancer Hospital

Recruiting

Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC (HER2-VIP)

HER2-positive Advanced Breast Cancer

China
Fujian Cancer Hospital

Recruiting

Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer

Colorectal Cancer

China
Fujian Cancer Hospital

Not yet recruiting

Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer

Colorectal Cancer
Fujian Cancer Hospital

Not yet recruiting

Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer

Gastric Cancer
Henan Cancer Hospital

Recruiting

Anrotinib Hydrochloride Combined With Adriamycin for Neoadjuvant Treatment of High-grade Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
Zhejiang Cancer Hospital

Not yet recruiting

Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

Second Line Treatment of Gastric Cancer
Fujian Cancer Hospital

Not yet recruiting

TIL Cells for the Treatment of the Advanced Solid Tumors Patients

Solid Tumor
Hunan Cancer Hospital

Recruiting

Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer

HR+/HER2- Breast Cancer

China
Fujian Cancer Hospital

Not yet recruiting

Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer

Esophageal Cancer
Henan Cancer Hospital

Not yet recruiting

Application of Antiosteoporosis Therapy in Osteolysis

Complication | Limb; Fusion

China
Zhejiang Cancer Hospital

Recruiting

DLCS for Predicting Neoadjuvant Chemotherapy Response

Gastric Cancer | Deep Learning | Neoadjuvant Chemotherapy | CT Images | Tumor Regression Grade

China
Henan Cancer Hospital

Not yet recruiting

Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes

Gastric Cancer | Gastroesophageal-junction Cancer
Henan Cancer Hospital

Not yet recruiting

Application of Douyin in Perioperative Period of Malignant Tumor Patients

Perioperative Period | Malignant Tumor of Bone
Zhejiang Cancer Hospital

Recruiting

A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastrointestinal Cancer (Excluding Biliary Tract Cancer) Patients With FGFR Alterations Who Have Failed Standard Therapy

Gastrointestinal Cancer

China
Zhejiang Cancer Hospital

Recruiting

Dynamic Contrast-enhanced MRI Combined With IVIM-DWI for Early Prediction of Chemosensitivity in Liver MBC (DreaminLMBC)

Metastatic Breast Cancer in the Liver

China
Zhejiang Cancer Hospital

Recruiting

TRT for ES-SCLC After First Line Treatment With Immune Checkpoint Inhibitors

SCLC,Extensive Stage

China
Fujian Cancer Hospital

Not yet recruiting

Elective Level Ib Irradiation in Nasopharyngeal Carcinoma Patients Based on the International Guidelines

Nasopharyngeal Carcinoma
Fujian Cancer Hospital

Not yet recruiting

the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy

Non-small Cell Lung Cancer Confirmed by Histopathology or Cytology | The TNM (8th) Phase is IV | With EGFR Mutations | Meningeal Progression Occurred After Previous Platinum-containing Two-drug Chemotherapy and Third-generation EGFR-TKI Treatment | Male or Female | The Age of 18 Years Old or... and other conditions
Henan Cancer Hospital

Not yet recruiting

A Study on the Potential Benefit of Neoadjuvant Therapy for AGC Patients

Early Gastric Cancer | Tumor Organoids
Zhejiang Cancer Hospital

Recruiting

SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors

NSCLC Stage IV

China
Hubei Cancer Hospital

Recruiting

Surufatinib With or Wothout Immunotherapy for Advanced Colorectal Cancer in Later Line

Colorectal Neoplasms

China
Henan Cancer Hospital

Recruiting

Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases

Breast Cancer

China
Zhejiang Cancer Hospital

Not yet recruiting

Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer

Stage IV Esophagus Squamous Cell Carcinoma

China
Zhejiang Cancer Hospital

Recruiting

ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL

Diffuse Large B Cell Lymphoma

China
Henan Cancer Hospital

Recruiting

Hyperthermic Intravesical Perfusion for Muscle-invasive Bladder Urothelial Carcinoma

Intraoperative Complications | Perfusion; Complications | High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma

China
Hubei Cancer Hospital

Recruiting

The Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors

Cancer Patients

China
Henan Cancer Hospital

Recruiting

Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer

Gastric Cancer

China
Zhejiang Cancer Hospital

Recruiting

The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer

Breast Neoplasm Female

China
Fujian Cancer Hospital

Recruiting

Short-term Outcomes of SILS+1 Versus CLS for Distal Gastric Cancer

Surgery

China
Henan Cancer Hospital

Recruiting

Real-World Effectiveness of Regorafenib in the Treatment of Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Fujian Cancer Hospital

Not yet recruiting

Apatinib Combined With Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer

Advanced Triple Negative Breast Cancer

China
Zhejiang Cancer Hospital

Not yet recruiting

RecurIndex Predicts Risk of Recurrence in Early-stage Luminal Breast Cancer

Recurrence | Breast Cancer
Fujian Cancer Hospital

Not yet recruiting

Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Hunan Cancer Hospital

Not yet recruiting

Research on Optimization and Evaluation of Oral Cancer Screening Methods

Oral Cancer
Henan Cancer Hospital

Recruiting

Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer (CAMERA)

Small Cell Lung Carcinoma

China

3

Subscribe